FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 327:1135-1140 October 15, 1992 Number 16 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. An increasing proportion of spending by the pharmaceutical industry has gone to funding symposiums that are published by peer-reviewed medical journals. This study tests the hypothesis that such sponsorship, particularly by a single pharmaceutical company, is associated with a promotional orientation of the symposium and a distortion of the peer-review process. METHODS. We counted the symposiums published in 58 journals of clinical medicine and surveyed the journal editors regarding their policies for symposium issues. We analyzed the symposium issues that appeared in the 11 journals that published the most symposiums in order to determine the sponsor or sponsors, the topics, whether the titles were misleading, whether brand names were used, and whether the featured drugs were classified by the Food and Drug Administration as innovative or approved. RESULTS. The number of symposiums published per year increased steadily from 1966 through 1989. Forty-two percent of those analyzed (262 of 625) had a single pharmaceutical company as the sponsor. These symposiums were more likely than those with other sponsors to have misleading titles (P less than 0.001) and to use brand names (P less than 0.001), and less likely to be peer-reviewed in the same manner as other articles in the parent journal (P less than 0.001). Of the 161 symposiums that focused on a single drug, 51 percent concerned unapproved therapies; 14 percent concerned drugs classified as bringing important therapeutic gains. CONCLUSIONS: Symposiums sponsored by drug companies often have promotional attributes and are not peer-reviewed. Financial relations among symposium participants, sponsors, and journals should be completely disclosed, symposiums should be clearly identified, and journal editors should maintain editorial control over contributions from symposiums.

Source Information

Institute for Health Policy Studies, School of Medicine, University of California, San Francisco 94109.

This article has been cited by other articles:

• Conen, D., Torres, J., Ridker, P. M (2008). Differential Citation Rates of Major Cardiovascular Clinical Trials According to Source of Funding: A Survey From 2000 to 2005. Circulation 118: 1321-1327 [Abstract] [Full Text]  
• Yank, V., Rennie, D., Bero, L. A (2007). Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study. BMJ 335: 1202-1205 [Abstract] [Full Text]  
• Cooper, R. J., Schriger, D. L. (2005). The availability of references and the sponsorship of original research cited in pharmaceutical advertisements. CMAJ 172: 487-491 [Abstract] [Full Text]  
• Lexchin, J., Cassels, A. (2005). Does the C in CME stand for "Continuing" or "Commercial"?. CMAJ 172: 160-162 [Full Text]  
• Leichter, S. B. (2004). Continuing Medical Education in Diabetes: The Impending Crisis. Clin. Diabetes 22: 174-177 [Full Text]  
• Tobin, M. J. (2004). Assessing the Performance of a Medical Journal. Am. J. Respir. Crit. Care Med. 169: 1268-1272 [Full Text]  
• von Elm, E., Poglia, G., Walder, B., Tramer, M. R. (2004). Different Patterns of Duplicate Publication: An Analysis of Articles Used in Systematic Reviews. JAMA 291: 974-980 [Abstract] [Full Text]  
• Shorter, E., Tyrer, P. (2003). Separation of anxiety and depressive disorders: blind alley in psychopharmacology and classification of disease. BMJ 327: 158-160 [Full Text]  
• Lexchin, J., Bero, L. A, Djulbegovic, B., Clark, O. (2003). Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326: 1167-1170 [Abstract] [Full Text]  
• Moynihan, R. (2003). Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: Entanglement. BMJ 326: 1189-1192 [Full Text]  
• Bryan-Jones, K., Bero, L. A. (2003). Tobacco Industry Efforts to Defeat the Occupational Safety and Health Administration Indoor Air Quality Rule. AJPH 93: 585-592 [Abstract] [Full Text]  
• Bekelman, J. E., Li, Y., Gross, C. P. (2003). Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review. JAMA 289: 454-465 [Abstract] [Full Text]  
• Ray, J.G. (2002). Judging the judges: the role of journal editors. QJM 95: 769-774 [Full Text]  
• Ripamonti, C., Sweeney, C., Bruera, E. (2002). Use of Trade Names of Drugs and the Scientific Content of Medical Congresses. JCO 20: 1707-1708 [Full Text]  
• Carpenter, W. T. Jr (2002). From Clinical Trial to Prescription. Arch Gen Psychiatry 59: 282-285 [Abstract] [Full Text]  
• Bero, L. A, Montini, T., Bryan-Jones, K., Mangurian, C. (2001). Science in regulatory policy making: case studies in the development of workplace smoking restrictions. Tobacco Control 10: 329-336 [Abstract] [Full Text]  
• Varkey, B. (2001). Time for Introspection. Chest 119: 1255-1256 [Full Text]  
• Cho, M. K., Shohara, R., Schissel, A., Rennie, D. (2000). Policies on Faculty Conflicts of Interest at US Universities. JAMA 284: 2203-2208 [Abstract] [Full Text]  
• DeAngelis, C. D. (2000). Conflict of Interest and the Public Trust. JAMA 284: 2237-2238 [Full Text]  
• Rennie, D., Luft, H. S. (2000). Pharmacoeconomic Analyses: Making Them Transparent, Making Them Credible. JAMA 283: 2158-2160 [Full Text]  
• Rennie, D. (1999). Editors and Owners--Stretching Reputation Too Far. JAMA 282: 783-784 [Full Text]  
• Davies, H. T. O., Rennie, D. (1999). Independence, Governance, and Trust: Redefining the Relationship Between JAMA and the AMA. JAMA 281: 2344-2346 [Full Text]  
• COHEN, J. E, ASHLEY, M. J., FERRENCE, R., BREWSTER, J. M, GOLDSTEIN, A. O (1999). Institutional addiction to tobacco. Tobacco Control 8: 70-74 [Full Text]  
• Flanagin, A., Carey, L. A., Fontanarosa, P. B., Phillips, S. G., Pace, B. P., Lundberg, G. D., Rennie, D. (1998). Prevalence of Articles With Honorary Authors and Ghost Authors in Peer-Reviewed Medical Journals. JAMA 280: 222-224 [Abstract] [Full Text]  
• Misakian, A. L., Bero, L. A. (1998). Publication Bias and Research on Passive Smoking: Comparison of Published and Unpublished Studies. JAMA 280: 250-253 [Abstract] [Full Text]  
• Barnes, D. E., Bero, L. A. (1996). Industry-Funded Research and Conflict of Interest: An Analysis of Research Sponsored by the Tobacco Industry through the Center for Indoor Air Research. Journal of Health Politics, Policy and Law 21: 515-542 [Abstract]  
• Aspinall, R. L, Goodman, N. W (1995). Denial of effective treatment and poor quality of clinical information in placebo controlled trials of ondansetron for postoperative nausea and vomiting: a review of published trials. BMJ 311: 844-846 [Abstract] [Full Text]  
• Bero, L., Barnes, D. E., Hanauer, P., Slade, J., Glantz, S. A. (1995). Lawyer Control of the Tobacco Industry's External Research Program: The Brown and Williamson Documents. JAMA 274: 241-247 [Abstract]  
• Hoberman, D., Puma, J. L., Cohen, S. N., Mossinghoff, G. J., Stryer, D. B., Bero, L. A., Kalish, R. S., Kessler, D. A., Rose, J. L., Temple, R. J., Schapiro, R., Griffin, J. P., Stern, R. S. (1995). Drug Promotion. NEJM 332: 1031-1033 [Full Text]  
• Cho, M. K., Bero, L. A. (1994). Instruments for Assessing the Quality of Drug Studies Published in the Medical Literature. JAMA 272: 101-104 [Abstract]  
• Rochon, P. A., Gurwitz, J. H., Cheung, C. M., Hayes, J. A., Chalmers, T. C. (1994). Evaluating the Quality of Articles Published in Journal Supplements Compared With the Quality of Those Published in the Parent Journal. JAMA 272: 108-113 [Abstract]  
• Chren, M.-M., Landefeld, C. S. (1994). Physicians' Behavior and Their Interactions With Drug Companies: A Controlled Study of Physicians Who Requested Additions to a Hospital Drug Formulary. JAMA 271: 684-689 [Abstract]  
• Bero, L. A., Galbraith, A., Rennie, D. (1994). Sponsored Symposia on Environmental Tobacco Smoke. JAMA 271: 612-617 [Abstract]  
• Rochon, P. A., Gurwitz, J. H., Simms, R. W., Fortin, P. R., Felson, D. T., Minaker, K. L., Chalmers, T. C. (1994). A Study of Manufacturer-Supported Trials of Nonsteroidal Anti-inflammatory Drugs in the Treatment of Arthritis. Arch Intern Med 154: 157-163 [Abstract]  
• Guyatt, G. H., Rennie, D. (1993). Users' Guides to the Medical Literature. JAMA 270: 2096-2097 [Abstract]  
• Angel, J. E., Massie, B. M., Rothenberg, D., Roberts, M. S., Kasper, C. K., Finucane, T. E., Bero, L. A., Galbraith, A., Rennie, D. (1993). Publication of Sponsored Symposiums in Medical Journals. NEJM 328: 1196-1198 [Full Text]